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“La gota és una malaltia crònica, inflamatòria i metabòlica, fortament lligada a altes 
concentracions d’àcid úric en sèrum (hiperuricèmia). Presenta una deposició de cristalls 
d’urat sòdic en les articulacions que causen una inflamació, és per això que se la 
caracteritza com un tipus d’artritis. Tot i que és molt coneguda i té varis fàrmacs pel seu 
tractament, s’ha vist que la dieta pot jugar un paper fonamental en la gestió de la 
malaltia. Per tant l’objectiu d’aquest estudi consisteix en determinar si un adequat 
control de la dieta, té el mateix grau d’impacte que el tractament farmacològic en la 
gestió de la malaltia. Durant l’estudi, s’ha dut a terme una recerca bibliogràfica en les 
principals bases de dades, on s’han seleccionat els articles més recents i rellevants. 
D’aquesta recerca s’ha pogut extreure informació sobre les bases  de la gota i les seves 
causes, en que consisteix el tractament farmacològic actual i quin impacte tenen els 
diferents tipus d’aliments i dietes en el desenvolupament de la malaltia. També s’ha dut 
a terme una petita entrevista a un pacient, que s’ha comparat amb la recerca. Finalment 
s’ha conclòs que un control apropiat de la dieta té un impacte similar al tractament 
farmacològic, sobretot en la reducció de la hiperuricèmia.” 
“Gout is a chronic, metabolic, and inflammatory disease, strongly related to high 
concentrations of serum uric acid. It is characterized by the deposition of monosodium 
urate crystals in the joint, which provokes an inflammatory process, and that is why it is 
characterized as a type of arthritis. Despite it being a well-known disease and several 
drugs being available for its treatment, evidence has shown that the diet plays an 
important role in gout management. Therefore, the objective of this study is to 
determine if proper diet control is as effective as the pharmacological treatment for 
disease management. For this study, bibliographical research has been conducted using 
the main scientific databases, where the most recent and relevant articles have been 
selected. The research has provided information on gout basis and its causes, the actual 
pharmacological treatment, and what impact the diet can have on the disease. Also, a 
short interview with a patient has been carried out and compared to the research. 
Overall, this study concludes that proper diet control has a similar impact in comparison 





• UA: Uric acid. 
• XO: Xanthine oxidase. 
• PRPP synthase: Pyrophosphate synthetase. 
• HGRPT: Hypoxanthine-guanine phosphoribosyltransferase. 
• IMP: Inosine monophosphate. 
• GMP: Guanosine monophosphate. 
• AMP: Adenosine monophosphate. 
• ATP: Adenosine triphosphate.  
• URAT1: Urate anion transporter 1. 
• OAT: Organic anion transporters.  
• SLC2A9: Glucose transporter 9. 
• EPA: Eicosapentaenoic acid. 
• DHA: Docosahexaenoic acid. 
• NSAIDs: Non-steroidal anti-inflammatory drugs. 














Integration of different fields 
 
Three important fields of study are discussed throughout this paper: Nutrition and 
Bromatology, Physiology and Physiopathology, and Pharmacology and Therapeutic 
Chemistry. The first is important for understanding the nutritional analysis of the 
disease, where purine concentrations on different types of foods are discussed. 
Nutrition is also important for the dietary management of the disease and for 
understanding which is the paper of the exogenous purines in gout. The second, 
Physiology and Physiopathology, are necessary for the disease presentation, diagnosis, 
mechanisms, and comorbidities. It also has an important role in uric acid metabolism 
and inflammation process comprehension. Thirdly, gout has a huge variety of drugs for 
its treatment, so Pharmacology is necessary to understand how these different drugs 
work and how they affect the uric acid concentration. These three fields are strongly 
related. For example, in the pharmacological analysis, physiology and pharmacology are 
involved, while in the nutritional section, nutrition and physiology are both discussed. 
Another example would be the treatment and the conclusions, where the research that 




Gout is a chronic, metabolic, inflammatory disease characterized by the deposition of 
monosodium urate crystals in the joints (1). The knees and fingers are the ones most 
commonly affected. The deposition of these crystals is linked to an increment in uric acid 
(UA) blood levels, known as hyperuricemia, which has two main causes, a reduction in 
the excretion of uric acid or an increase in its production.  
This disease is characterized as a type of chronic arthritis, which switches between 
periods of exacerbation, where the patients can experience really painful episodes in 
the joints, and latency periods where the symptoms disappear. It is important to keep 
in mind that there are some human behaviors than can precipitate an episode, such as 
eating or drinking certain types of food, increased alcohol intake, or treatment with 
certain drugs. 
For centuries, gout has been present in human history, known as the main chronic and 
inflammatory disease. Years ago, it was related to a high social status because wealthy 
people had access to high purine foods that poorer people did not. These days, people 
across all social classes can access these different foods types, increasing the impact of 
gout across society. The purpose of this work is to discuss the basis of the disease and 
find out which food types have an effect, looking for ones that can be preventative, as 
well as ones that will be more likely to cause an attack. At the same time, the paper will 
discuss the treatment of the disease using drugs, as well as via the diet, looking to see if 
there is any interaction between the foods and the medication. 
2. Objectives 
Hypothesis: A proper diet control is as effective as the pharmacological treatment for 
gout management.  
Associated objectives: 
• Apply correctly the databases. 
• Set the basis of the disease.  
• Identify which foods are related to the disease and their impact. 
• Understand the role of drug treatment in the metabolic processes. 
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• Evaluate the comorbidities impact on gout management. 
• Evaluate the impact of diet on patient health. 
3. Methods and Materials 
This is a bibliographic research project. The research methods were taught through 
seminars by the library of the pharmacy faculty from the University of Barcelona (CRAI) 
as well as the tools used for developing the research. The tools and research 
methodology include academic access to electronic databases, which provided access 
to a large number of scientific articles. The principal databases used for this project were 
PubMed, Scopus, and PMC. Even though most articles were found through these 
databases, the official web page of the American College of Rheumatology was also an 
important resource.  
The articles were selected due to their matching criteria with the topics of this project. 
Each one has been read and analyzed carefully. Although the research is based on the 
most recent information on each topic, some older articles are discussed. This is because 
they were either considered primary research or they were mentioned in more recent 
articles.  Finally, for the bibliographical development, the reference manager Mendeley 
was used, and through the tool Mendeley Microsoft Word plugin, the articles had been 
cited through the document. The bibliography citations follow the Vancouver rules and 
the scientific citation criteria. 
After the bibliographic research has been done, it has been compared with a patient 
interview, to see if the information found, matches with a real case. The interview had 
been done face to face with the patient, and specific questions about gout and the 
patient's health status have been collected. All the information have been collected 
anonymously and scientifically, and the rules for a patient-pharmacist interview 
provided on the " Guía Práctica para los Servicios de Atención Farmacéutica en la 
Farmacia Comunitaria" (2) have been adapted.  The questions were highly related to the 





4. Results (Research development) 
4.1.  Pathophysiology 
 
UA is one of the most important concepts to consider when talking about gout and its 
pathophysiology.  UA is a product from the metabolism of endogenous and exogenous 
purines, the nucleotide bases adenine and guanine, carried out mostly by the liver (3). 
The exogenous purines come from the diet, while the endogenous are derived from 
cellular metabolism. 
Several enzymes participate in purine metabolism (Figure 1), and a lot of different 
reactions take place to convert purines to the final product, UA. One of the most 
important enzymes involved in this process is xanthine oxidase (XO), which converts one 
of the final products of purine metabolism, hypoxanthine, to UA. This enzyme is one of 
the main targets for gout therapy. Apart from XO, the enzymes phosphoribosyl 
pyrophosphate synthetase (PRPP synthase), purine nucleoside phosphorylase and 
hypoxanthine-guanine phosphoribosyltransferase (HGRPT) are also important because 








Figure 1: Diagram of purine metabolism 
Retrieved From: Fathallah-Shaykh Sahar, T. Cramer Monica. Uric acid and the Kidney. Pediatric nephrology. June 2014, Volume 29. 
Pages 999-1008. Doi: https://doi.org/10.1007/s00467-013-2549-x 
PRPP synthase is involved in the conversion of a sugar metabolite (Ribose-5-Phosphate) 
to inosine monophosphate (IMP), which is an intermediate between the two purine 
bases, adenosine, and guanosine. Then purine nucleoside phosphorylase converts that 
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inosine into hypoxanthine which is the substrate for XO. Meanwhile, HGRPT and APRT 
(adenosine phosphoribosyltransferase) are part of the purine salvage pathway, which 
converts the purine bases to guanosine monophosphate (GMP) and adenosine 
monophosphate (AMP) respectively, molecules that then can be converted to 
hypoxanthine. Uricase converts UA to a more soluble molecule called allantoin. 
Unfortunately, in humans uricase is inactive due to a nonsense mutation.   
Pathological hyperuricemia occurs when the serum concentration exceeds 408 μmol/L 
[6.8 mg/dL] (4) and could be due to different reasons. The main one is a reduction in UA 
excretion and two organs are involved in this process. The first one is the kidney, which 
is responsible for 66% of the elimination. The other 33% occurs in the gastrointestinal 
tract (5).  
Taking into consideration that UA is not very soluble in aqueous solutions, it is found in 
physiological fluids as urate, the UA anion. However when this anion leaves the 
bloodstream and goes to the urine, where the pH changes from 7.3-7.5 to 5.0-6.0, then 
it switches again to UA, affecting its solubility and transport (3). In the kidney, epithelial 
membranes exchange UA in both directions, between the interior of the cell and the 
lumen.  This fact is important because an increased absorption or decreased excretion 
will affect the UA concentration in the bloodstream.   
The mechanism that regulates UA excretion is not totally understood, but there are 
some membrane transporters involved (Figure 2): Urate anion transporter 1 (URAT1) is 
responsible for the reabsorption of urate after glomerular filtration. Organic anion 
transporters (OAT1 and OAT3) and glucose transporter 9 (SLC2A9) mediate urate 











Figure 2: Urate excretion in the kidney 
Retrieved from: Dalbeth Nicola, Tony R Merriman, K Stamp Lisa. Gout. The Lancelet, Volume 388, 22–28 October 2016, Pages 
2039-2052. Doi: 10.1016/S0140-6736(16)00346-9 
Different factors can affect the excretion of UA. An increased exogenous intake can be 
one of them and it will be discussed later in this paper.  Some medications, for example, 
diuretics, can affect the tubular transport changing the secretion or absorption of UA (3) 
Changes in the extracellular fluid can also affect the excretion. If extracellular volume 
increases, it will be detected by the central nervous system (SNC). In response, this will 
decrease the reuptake and increase the excretion of water and electrolytes as well as 
UA. Alternatively, if the volume gets reduced it means there will be more reuptake 
because the SNC detects a lack of liquid, then UA will be reabsorbed.  
Another possible cause of an increased UA concentration is enhanced production (3). 
This normally occurs because there is increased purine degradation in somatic cells, 
which ends up with more production of UA in the liver. It is usually related to rapid cell 
proliferation or turnover, for example, leukemias and lymphomas.  The increased 
production can also be related to enzymatic causes linked with the enzymes discussed 
earlier, PRPP synthase, HGRPT, purine nucleoside phosphorylase or XO. Enzyme activity 
variations could be a complete deficiency, a partial deficiency, or an increased activity. 
One example could be a partial or a complete deficiency of HGRPT (called Kelley –
Seegmiller syndrome and Lesh-Nyan syndrome respectively). Without this enzyme 
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guanine cannot be converted back to GMP, letting it go into the salvage metabolic 
pathway, increasing the UA formation. Another example could be an increased activity 
of PRPP, making a higher amount of IMP, which is metabolized to UA (Figure 1). 
Once UA concentration is high, there is a tendency to develop crystals of urate in the 
joints. More specifically they are monosodium urate crystals because the uric acid gets 
combined with sodium ions (4). It is not clear which factors are involved or why the 
crystal formation occurs, but there are some things that all those who suffer from gout 
have in common. The first one is hyperuricemia, followed by a drop in the temperature 
(7). A clear example is the fingers. As a part of the body that is far away from the core, 
they normally have a lower temperature, which makes it easy for the UA to lose 
solubility and produce these pathological crystals. Variation in pH may also have an 
effect, although reports on this topic are not clear. This means that some other factors 
must be considered. Research suggests that an increase of sodium concentrations 
increases the probability of urate monosodium crystals formation.   
Deposition of urate crystals in the joints results in an inflammatory response, as they are 
an external and non-recognized agent (Figure 3) (8). This leads to the pathology known 
as gout. This inflammatory response is initiated by macrophages, which interact with 
urate crystals and create inflammasomes. This promotes the production of some 
inflammation factors such as interleukin 1-β (4), and the response is amplified by 
neutrophils and mast cells. Finally, the tissue is invaded by pro-inflammatory cytokines 
and prostaglandins. When this happens the first symptoms appear, the most common 












Retrieved from: NicolaDalbeth, Thomas J.Lauterio, Henry R.Wolfe. Mechanism of Action of Colchicine in the Treatment of Gout. 
Clinical Therapeutics. October 2014. Volume 36. Pages 1465-1479. Doi: https://doi.org/10.1016/j.clinthera.2014.07.017 
 
4.2. Signs and Symptoms 
 
Gout is characterized by flares that are a painful 
feeling in the joint where the crystals are formed, 
related to an acute episode of inflammation (1). 
The symptoms presented are pain, swelling, heat, 
redness, and difficulty in moving the affected joint 
(4). Also, before a flare occurs, the individual can 
feel discomfort or tingling in the affected zone, 
normally about 24 hours before the flare occurs. A 
flare can last for one week or two but can be 
resolved earlier if the patient uses medications. 
Examination during a flare will show synovitis, which means an evident joint 
inflammation, with pain on contact (Figure 4). There is a pronounced tenderness and 
tendinitis and bursitis can be present. In severe cases, a polyarticular flare (more than 
one joint affected) can be present and the patient can experience fever. Also, some can 
have subcutaneous nodules called tophi, but those are normally pain-free (9). 
 
 
Figure 4: Joint inflamed due to 
crystal deposition. 
Medecinenet [Internet]. San Clemente, 2016. 









An important thing to take into consideration is the existence of risk factors that can 
always help diagnosis (1); these are described in Table 1 and need to be adjusted by the 
age of the patient. Proper diagnosis is normally done using the American College of 
Rheumatology criteria (10). These utilize different options: the first one is the presence 
of urate crystals in the joint fluid, the second one is the presence of tophi plus urate 
crystals (determined by laboratory techniques) and the third one is the presence of six 










Different laboratory techniques are used for diagnosis. The main one uses polarizing 
light microscopy of the synovial fluid or tophus for finding urate crystals, which will 
appear as needle-shaped in the microscope (4). Testing UA in the blood is also helpful 
for the diagnosis, but hyperuricemia is not enough by itself to confirm gout. If joint 
aspiration is not available, it is helpful to use imaging modalities to assist in the diagnosis. 
Radiography helps to see joint erosion in advanced gout, or ultrasonography might show 
features of monosodium urate crystal deposition. 
 
Risks factors 
Alcohol intake  ≥ 50g /day  
Hypertension − 
Body mass index  ≥ 30kg/m2 
Sweetened drinks ≥ 2 drinks /day 
Fructose intake  Highest quintile 




Vitamin C intake < 250 mg 
Table 1: Different risk factors related to Gout development 






4.4. Nutritional factors 
 
4.4.1. High purine foods 
It has been shown that a diet with a greater intake of meats and seafood is related to a 
higher level of UA blood concentration and as a consequence, a greater probability of 
developing gout (11,12). It is important to understand that not all types of meats have 
the same risk. Pork, beef, and lamb are more harmful than chicken and turkey.  
The cause of the increased UA level in blood is twofold. First, there is an increase in 
exogenous purines, causing the body to produce more UA than normally does. Also, an 
increase of red meat (pork, beef, lamb) is related to an increase in dietary saturated fat, 
which is related to a decreased excretion of urate in the kidney (11). The way a diet rich 
in saturated fats decreases urate excretion is not fully understood, and the data are not 
clear about it. Some of the hypotheses at the moment are increased retention by the 
tissues, diminished production of endogenous purines and disturbances of the function 
of the liver. The metabolism of high-fat diets results in an acidosis and ketosis acidosis 
situation in the body, which ends up in a decreased in excretion of UA, but this effect 
Diagnostic criteria for gout 
Presence of characteristic urate crystals in the joint fluids 
Presence of a tophus proven to contain urate crystals by chemical means or polarized light 
microscopy  
Presence of six or more of the 
following clinical, laboratory or 
radiological findings:  
Asymmetric swelling within a joint on radiography 
Attack of monoarticular arthritis 
Culture joint fluid negative for microorganisms during an 
attack of joint inflammation. 
Development of maximal inflammation within one day. 
Hyperuricemia. 
Joint redness. 
More than one attack for acute arthritis 
Pain or redness in the first metatarsophalangeal joint. 
Suspected tophus. 
Subcortical cyst without erosions on radiography. 
Unilateral attack involving first metatarsophalangeal joint. 
Unilateral attack involving tarsal joint. 
Table 2: Rules followed to diagnose gout in a patient. 
• Adapted from: Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute 





can be balanced with a good carbohydrate and protein intake, but why these effects 
balance each other are still unclear (11).  
However, a high protein diet is not necessarily related to an increased circulating UA and 
the development of gout. It will also depend on the sources from where this protein 
comes. For example, if the main source is red meat or seafood there will be a greater 
possibility of increasing circulating UA concentrations. Also, a higher concentration of 
purine in food does not necessarily mean that UA blood levels will increase (11). For 
example, spinach, which has more purines than a raw steak (171mg/100g vs 90.2 
mg/100g) (13), does not increase UA levels in serum. So, there are a lot of factors that 
can affect the relationship between food and its effect on circulating UA concentrations, 
the quantity of the food, the cooking practice, the type of purines present in the food, 
and the different bioavailability of the purines are all important. For example, some 
studies have shown that the process of boiling, steaming or microwaving can reduce the 
purine content in foods; boiling is the process which decreases purine content the most 
(14). This happens because boiling makes an extraction of purines from the foods to the 
water, risen the purine content in the cooking liquid. 
4.4.2. Alcohol 
There is a well-known relationship between alcohol and gout, but the risk of 
hyperuricemia and gout varies with the amount and type of alcohol consumed. Is seems 
that the alcohol affects UA circulating levels by increasing exogenous purines (beer) 
(11,12), increasing the endogenous production, and decreasing the urate excretion in 
the kidney. Compared to non-alcoholic diets, the ones which contain beer or liqueur 
every day are more likely to increase serum urate concentration. Beer has a greater 
effect than liqueur, and the more of each compound consumed, the higher the risk 
(15,16). Wine does not appear to be associated with an increase in urate concentration. 
There is a difference between sexes, since women got higher serum urate levels than 
men for the same amount of alcohol consumed. 
 A possible mechanism by which alcohol increases urate is because it increases 
adenosine triphosphate (ATP) conversion to AMP for alcohol metabolism which ends up 
in an increased production of UA(12). Another explanation of why beer enhances UA 
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more than liqueurs is because it contains a large amount of purines, increasing the 
exogenous intake. Beer yeast contains 2995 mg/ 100mg (13). Another theory about why 
alcohol decreases UA excretion could be because alcohol is converted to lactic acid in 
an acute and excessive intake and this acid competes with the excretion of UA in the 
kidney. 
4.4.3. Fructose and sweetened drinks  
Fructose is the only carbohydrate that increases urate blood levels. So consuming soft 
drinks, which normally have a high concentration of fructose, is related to an increased 
incidence of hyperuricemia and therefore gout (11,12,17). There is a direct relationship 
between the number of sodas consumed and the risk of gout which can be more severe 
depending on the ethnicity. As a example, consumption of soda leads to a 6,89 % greater 
chance of developing gout in white people but only a 1,48 % greater chance in pacific 
island's natives (18). These difference between the races is due to the polymorphism in 
the SLC2A9 gene.   
Although soft drinks have a very low amount of purines, they contain is a high fructose 
concentration. The metabolism of fructose involves high consumption of ATP, which 
generates AMP in the liver, which will be finally metabolized to UA. Besides, there is an 
indirect factor which can increase UA levels, because a higher fructose intake is related 
to insulin resistance. It increases the glucose concentration in the blood, making the 
body generate more insulin, which decreases the UA kidney excretion. The insulin effect 
on UA excretion is not completely understood, is it not clear if it inhibits UA secretion in 
the tubule or increases UA reabsorption at the tubular level (19). The main theory right 
now suggests that insulin changes the extracellular volume near the blood vessels 
surrounding the tubules, affecting UA excretion.  
Other foods, which also can have high fructose concentrations are fruit juices, apples, 
or acid fruits (mandarin or oranges). There is a significant relationship between juice 
consumption and gout risk and the same applies to apples and oranges (20). However, 
the risk is lower than sweetened beverages (21). The data are not clear about the 
number of fructose calories necessary to cause an increase in the circulating urate, so 




4.4.4. Low-fat Dairy products 
Dairy products have a very low amount of purines, for example, milk has no detectable 
purines(13). These products are related to lower levels of urate in the blood, in a 
comparison between a dairy-free diet and dairy inclusive diet, the first one increases the 
UA levels. Also the intake of milk at least once a day decreases significantly the incidence 
of gout (22). 
Dairy consumption decreases the urate levels because of the uricosuric effect of milk 
protein in the kidney. Milk contains orotic acid (11), which competes with the urate for 
the kidney transporter URAT 1, reducing urate reuptake, which means there will be 
more excretion of UA. Also, dairy protein and fat can module the inflammatory response 
to monosodium urate crystals, they may have a similar effect as colchicine, a drug that 
will be discussed later in this paper.  
4.4.5. Coffee/Tea 
There appears to be an inverse relationship between coffee intake and blood urate 
levels. However, the studies do not show any difference between decaffeinated coffee 
and normal coffee, so a compound in this beverage other than caffeine has to be 
responsible for this effect(11,12,23). Tea, by the way, seems not to be related to urate 
serum concentrations. It is important to consider that more research has to be done 
because the data are not sufficient. 
4.4.6. Vegetables and fiber:  
Vegetables are linked with lower UA levels, maybe because they increase UA kidney 
excretion, but data are not clear(12). Fiber intake also has an inverse relationship with 
urate serum concentrations. These could be because fiber reduces nutrient absorption 
in the gut, making a decreased intake of exogenous purines. When fiber arrives in the 
gastrointestinal tract, it increases the rate of passage, which could potentially decrease 






4.5.  Anti-inflammatory nutrition 
 
Even though foods can increase or decrease circulating UA levels, there is another 
characteristic that should be considered, the anti-inflammatory effect. The fact that 
some foods can have some anti-inflammatories properties, can help to reduce flares 
frequencies.   
4.5.1. Omega 3 fatty acids, EPA (eicosapentaenoic acid) and DHA 
(docosahexaenoic acid) 
As is discussed above in this paper, seafood and bluefish have a high content in purines, 
increasing the risk of high levels of circulating UA (12,13). However, these foods also 
contain EPA and DHA, fatty acids with anti-inflammatory properties (25). These two fatty 
acids regulate genes, which are involved in multiple processes, including inflammation. 
To notice the therapeutic effect of EPA and DHA is important to administrate enough of 
these two compounds to make the dose effective (25). 
 These Omega-3 fatty acids regulate the signaling pathways and genes expression of 
immune cells, for example, a study of the Nutrients journal says that the administration 
of EPA and DHA in lipopolysaccharide-stimulated THP-1 macrophages, induce changes 
in the gene expression that may protect macrophages from an excessive inflammatory 
response (25). However, this is not the only mechanism related to inflammation 
reduction. They also showed a rapid and selective inhibition effect on the NLRP-3 
inflammasome, through G protein-coupled receptors (26).   
Knowing the possible action mechanisms, is clear that omega-3 fatty acids help reducing 
inflammation (25,26). But, the source of EPA and DHA also contains a great number of 
purines, so an evaluation of fatty fish intake must be considered (11–13). As it appears 
in an article of the American College of rheumatology, while the consumption of fatty 
fish helps reducing flare attacks, the omega-3 fatty acids supplements did not (26). 
These differences between the main source and the supplements could be because the 
supplements, don't reach the same dose as fish does (26). Despite fatty fish reduces the 
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possibility of flare attacks, if they are consumed in a rich purine diet, they can increase 
the possibility of high UA blood levels, because of its rich purine content (11–13,25,26). 
4.5.2. Turmeric 
Turmeric or curcumin is a spice that comes from the rhizome of the plant Curcuma Longa 
and it has been recognized with different medical properties, thanks to its major 
polyphenol, curcumin (27). It aids modulating de inflammatory response, oxidative 
stress and metabolic syndrome, characteristics which can make this spice helpful for the 
flare attacks (27,28). The anti-inflammatory mechanism of curcumin is based on blocking 
the activation of the nuclear factor- KB (NF-KB), which regulates the expression of the 
tumor necrosis factor α (TNF-α), an important mediator on the inflammatory process 
(27). The activation of NF-KB can occur through multiple ways including oxidative stress, 
that is why curcumin is helpful against this process (27). 
For these different properties, curcumin has seen to be useful during osteoarthritis and 
that is why it can be useful for chronic arthritis pathologies. There is a study from the 
Baqiyatallah University of Medical Sciences that had made a randomized double-blind 
placebo-controlled trial (28). The study shows a significant reduction of pain, and an 
improvement in joint function, in the treatment group compared with the placebo ones. 
The treatment consisted of a daily dose of 500 mg curcuminoid with 5 mg of piperine 
for 6 weeks (28). It is important to consider that these improvements were not related 
to a decrease in the circulating cytokines, they were related to the changes in the 
synovial cytokines, for this reason, it is possible, that curcumin effects are more related 
to a local anti-inflammatory effect rather than a systemic one (29). Another study shows 
that curcumin could have the same beneficial effects as non-steroidal anti-inflammatory 
drugs (NSAIDs) have (30). Even though the effects of the drug were faster than curcumin, 
for long term administration, they show similar outcomes. This is the reason why 
curcumin could be a proper substitute for NSAIDs, especially when these drugs cause 
severe gastrointestinal effects (30). 
Therefore, curcumin has perfect properties to deal with inflammation, there is an 
inconvenient related to it, its low bioavailability (27,28). It has poor absorption, rapid 
metabolism, and rapid elimination. However, there are some different agents which can 
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help this bioavailability to increase, for example, piperine, the major component of black 
pepper (28). By blocking the curcumin metabolic pathway, piperine enhances curcumin 
bioavailability (27). That is why in the study discussed above, they add 5 mg of piperine 
to the curcumin complex. Despite its low Bioavailability, there is no discussion that 
turmeric presents multiple medical properties, and it helps to reduce the oxidative 
stress and inflammation, which makes this spice important to consider for gout 
treatment. (27–30). 
4.5.3. Vitamin C 
Vitamin C or ascorbic acid is an essential nutrient that we can find in numerous fruits 
and vegetables, besides that, this substance also presents two beneficial effects in gout 
patients (20). Vitamin C had shown the trait of increasing UA excretion through urine, 
reducing the serum UA. This effect is due to the vitamin C transporters (SLC23A1, 
SLC23A2) can modify URAT1 (responsible of UA reabsorption) activity in the proximal 
tubular cells, even the mechanism is not fully understood, the proximity of these 
transporters in the apical membrane of the proximal tubular cells, suggest that they can 
interact with each other (20). The other beneficial effect is blocking the pro-oxidative 
stress of fructose and UA, which is a source of inflammation (20,31). Vitamin C as an 
antioxidant substance acts neutralizing free radicals of the oxidative stress by being an 
electron donor (20,31).   
Looking at the action mechanisms, Vitamin C can be considered on diet management 
for gout. However, as it is discussed on the omega 3 fatty acids, the vitamin C source 
also can be a problem, because fruits and juices are known to have a high fructose 
content, which is prejudicial for gout management as is discussed above (11,12,20), 
that’s why, a risk-benefit for each food should be examined, choosing the sources that 
have less fructose and more Vitamin C, for example, broccoli (31).  
4.5.4. Cherries 
This fruit, according to different articles, had appeared to be related to lower UA 
circulating levels and a gout flares reduction (32). Cherry presents an anti-inflammatory 
mechanism, it inhibits cyclooxygenase 1 and 2 due to anthocyanin, a flavonoid present 
in the cherry extract (32,33). The extract also appears to reduce urate crystals stimulated 
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inflammatory cytokines in affected joints (33). Another important cherry effect is the 
capacity of lowering serum urate, by inhibiting XO (32,33).  
Despite the mechanisms are promising, data is not significant enough, and more 
research should be done, especially in the serum urate-lowering capacity (33). Another 
aspect that must be considered about cherries, is that they present vitamin C, and as it 
is discussed above, it is another important compound for gout management. In resume, 
although more research is needed, cherries may be helpful for gout management in both 
stages, flare attacks, and urate-lowering therapies (32,33). 
 
4.6. Pharmacological analysis 
 
For gout treatment, two scenarios have to be considered, the acute treatment which 
involves the flares, and the long term one, which uses urate-lowering drugs (1). The flare 
treatment includes corticosteroids, colchicine, and NSAIDs (non-steroidal anti-
inflammatory drug). In the acute case, the treatment should start as soon as possible 
when a flare appears, and patients need an action plan and easy access to the drugs to 
make the attack last as few days as possible. Long term treatment is only recommended 
for people whose flares have become chronic (more than 2 flares a year) or have tophi 
present, or patients with other comorbidities, for example, chronic kidney disease. 
Having hyperuricemia, but no other symptoms is not enough to include the urate-
lowering therapy (4). 
The urate-lowering therapy target is to reach 6 mg/dL of circulating urate in the blood 
(10). At this serum concentration, monosodium urate crystals will be more likely to 
dissolve. An important consideration of this therapy is that it can precipitate flares when 
it is introduced, due to mechanisms that will be discussed later in this paper. The 
recommendation for avoiding this problem is doing prophylaxis with anti-
inflammatories for 6 months before the urate-lowering therapy starts (34). 
Long term therapy should start after a flare occurs, and then last till the desired urate 
concentration (6 mg/dL) in serum is achieved. Normally it takes between three to six 
months. After this time if, there has not been any symptoms, the patient can stop taking 
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the medication. In case any of the symptoms of a flare occurs, the prescription should 
be continued indefinitely (4). A worrying problem with this therapy is that it has a very 
low adherence (10-46%) (35) , so it is important to make the patient aware of the disease 
and urate levels. Patient’s understanding of the chronic nature of the disease is essential 
to successful gout management.  
4.6.1. Urate lowering drugs 
Allopurinol 
Allopurinol is a first-line therapy, which means it is the first option to give to a patient. 
It is also a "predrug", so bioactivation is required. This means that the allopurinol 
metabolite oxypurinol is the one that makes the pharmacological action. Oxypurinol is 
an XO inhibitor, that blocks the last 2 reactions of purine metabolism. Allopurinol is 
normally excreted by the kidney and there are no contraindications, although some 
individuals have a sensitivity to it. The dosing varies between 50-900 mg/ day, but for 
doses above normal (300 mg/day) should be monitored (4). It has some interactions but 
the most important one is with diuretics, which can increase the possibility of allopurinol 
hypersensitivity syndrome. Patients with a decreased renal function should not take it 
for reasons explained later in this paper. There is a study that found that allopurinol can 
also reduce XO expression, but more research is needed (36).  
Febuxostat 
Febuxostat is also a first-line treatment for gout and it also inhibits XO (Figure 5). 
Although it has been shown to be more effective than allopurinol to decrease the serum 
concentration of urate, it is not more effective in reducing the flare frequency. This drug 
is metabolized in the liver by conjugation with glucuronic acid or by oxidation (3). There 
is no other side effect except for possible hypersensitivity. Both, allopurinol and 
febuxostat, can cause acute attacks at the start of the treatment, since it takes a long 
time for the drugs to control urate levels (34). 
Probenecid 
Probenecid  does not inhibit any enzyme, it is a diuretic that increases the urinary 
excretion (Figure 5) of UA by inhibition of a tubular anion transporter, which is involved 
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in urate reuptake (37). It specifically inhibits the URAT and OAT transporters (Figure 2). 
It is metabolized in the liver by conjugation and excreted for the kidneys.  Normally, it is 
used as a second-line treatment because it has a lot of drug interactions, making it 
dangerous if combined with other drugs (ex: methotrexate), which could result in severe 
toxicity. It can be used in combination with XO inhibitors if they are not enough for 
lowering serum urate levels. One important side effect is that it can make UA stones in 
the kidney, so a high fluid intake is important, to avoid this problem (37). 
Benzbromarone 
Benzbromarone increases renal urate excretion by inhibition of the tubular transporter 
URAT 1, blocking urate reabsorption. Its indication is the same as probenecid. It is 
metabolized in the liver and is mainly excreted in bile and feces (4,38). It is strongly 
contraindicated in patients with excess of alcohol intake and liver diseases for metabolic 
reasons. It also presents numerous interactions with other drugs, for example, warfarin 
(it increases the anticoagulant effect), and also with fluconazole and rifampicin (38). As 
side effects it can also produce kidney stones, so high liquid intake is recommended. As 
a uricosuric, it is more powerful than probenecid, being effective in patients that have 
decreased filtration rates. However, it is not used because of the possible hepatotoxicity 
that it presents.  
Pegloticase 
Pegloticase is an intravenous drug. It is an exogenous uricase, that will convert UA to its 
more soluble metabolite allantoin (Figure 1)  that is excreted by the kidney (39). Due to 
the administration form and possible side effects, it is a third-line treatment and is only 
used in refractory gout, where the other treatments have failed. The dose is 8 mg every 
two weeks and is administrated by a rheumatologist. It cannot be used at the same time 
as other urate-lowering therapies. It presents important side effects such as 





Figure 5: Action places of gout drugs. 
Retrieved from: Richette Pascal, Garay Ricardo. Novel discovery strategies for gout. Expert opinion on Drug discovery. Dec 2012. 
Volume 8. Pages 183-189. Doi: 10.1517/17460441.2013.742061 
 
4.6.2. Acute Gout treatment 
Colchicine 
Colchicine is used in both therapies, urate-lowering therapy, and flare treatment. The 
mechanism of action is the prevention of microtubules assembly which will inhibit the 
inflammatory response to the urate crystals deposition (Figure 3) (8). Because 
microtubule assembly is present in the majority of inflammatory processes, the 
utilization of colchicine is being studied in other inflammatory chronic diseases (1). 
Colchicine is used to prevent gout flares at 0,6 to 1,2 mg of dose, but drug administration 
is quite particular: when a flare occurs, the patient should start with 1.2 mg initially, 
followed by 0.6 mg after 1 hour. The maximum dose is 1.2 mg a day, though this can 
change if the patient has kidney disease (4). Also, it has important interactions with CYP 
4503A4 and P glycoprotein inhibitors (for example diltiazem and ciclosporin 
respectively). As side effects this drug presents reversible axonal neuromyopathy (8). 
Patients should take care if any symptoms or signs appear then and discontinue the 




Non-steroidal anti-inflammatory drugs (NSAIDs)  
NSAIDs are the first-line treatment when a flare occurs. The most common one is 
indomethacin, but other ones, for example, naproxen or ibuprofen are good too. The 
mechanism of action is by inhibiting the enzymes cyclooxygenase 1 (COX 1) and 
cyclooxygenase 2 (COX 2) (40). The first one is a gastrointestinal protector enzyme and 
the second one modulates the inflammatory response. The inhibition of COX1 will cause 
gastrointestinal side effects, and the inhibition of COX2 has the main therapeutic effect. 
There are some COX2 specific inhibitors, but they do not seem to be more effective than 
the nonspecific ones. Any NSAID is given at its max dose when an attack appears and is 
continued one or two days after the symptoms have disappeared. For example, 
indomethacin, should be taken 50 mg three times per day. This drug could be 
contraindicated if the patient has any kidney disease, cardiovascular problems or 
gastrointestinal diseases, due to the side effects that this type of drug can present (40). 
As secondary effects, there is the gastrointestinal damage due to the lack of 
prostaglandin production in the stomach. Another secondary effect is an increase in 
cardiovascular disease by increasing blood pressure and lowering kidney function, 
especially in long terms treatments (40).  
Corticosteroids 
These drugs are not a first-line treatment and are an alternative for patients who cannot 
take colchicine or NSAIDs or have several comorbidities. The mechanism of action is the 
same as endogenous steroids, they react with type 3 steroid receptor, which will 
produce an anti-inflammatory response. When there are only one or two joints affected, 
intraarticular corticosteroids could be effective. If not, normally oral prednisolone is the 
one used, at the dose of 35 mg/day (1). The principal side effect is the corticosteroid 
rebound, that can happen when the patient stopped taking the medication, so the dose 






4.7. Gout and comorbidities 
 
It has been noticed that gout is associated with different comorbidities like heart and 
renal diseases, which a lot of times are highly related to hyperuricemia. These 
comorbidities are one of the most important causes of death for gout patients (36). Also, 
the prevalence of metabolic syndrome, related to gout disease is high, frequently the 
patients show hypertension, abdominal obesity (body max index and waist 
circumference elevated), Type 2 diabetes and hypertriglyceridemia. The presence of 
these signs is higher in gout patients compared to non-gout individuals (41). 
Asymptomatic hyperuricemia can cause other effects in the body apart from gout (1,4). 
It can cause the metabolic syndrome mentioned above and renal arteriosclerosis, which 
means the deposition of fatty molecules in the vascular walls, making the passage 
narrower, and the blood will have difficulties to circulate. Other effects that a higher 
blood UA concentration can make to the body are decreasing nitric oxide production by 
limiting enzyme activity, activating the renin-angiotensin system, and increasing insulin 
resistance, which will end up increasing the cardiovascular risk (42).  
Cardiovascular mortality increases with gout due to the high levels of UA in blood and 
the inflammation produced for crystal deposition (41). Gout medication does not help 
this problem because NSAIDs and diuretic side effects are related to cardiovascular 
problems (34). As said before hyperuricemia is one of the most important factors related 
with the increased cardiovascular risk. There are many different studies that support a 
relation between high circulating UA levels and an increased frequency of cardiovascular 
death: stroke, atrial fibrillation, and heart failure (42). 
Another factor to consider with cardiovascular disease is XO enzyme. As it is a redox 
enzyme it can produce free radicals (Figure 6). With a normal enzyme function, this 
should not be a problem but with increased activity, for example, more purine 
metabolism, it can end up creating more free oxygen species (42). These radicals will 
cause damage due to oxidative stress in the vascular endothelia and the inhibition of NO 
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production. However, is it unclear for the moment if this problem is due to an increased 
XO activity or due to an increased circulation of soluble UA(42). 
 
 
Figure 6: XO mechanism, and production of oxygen free radicals. 
Retrieved from: Pathak, Khanin & Rahman, Syed & Bhagawati, Sudhansu. (2017). Chemical Science Review and Letters An 
Overview of Antioxidant and free Radicals-A Review Article. 2017. 242-251.URL: 
https://www.researchgate.net/publication/319483353 
There is a high prevalence of chronic kidney disease (CKD) in gout patients. The main 
problem with this comorbidity is that it will decrease urate excretion in urine, increasing 
the probability of originating gout. In addition the risk of end-stage renal failure is higher 
in gout patients because different problems can appear (36,41). These include 
accumulation of monosodium urate crystals in renal tubules, the possibility of kidney 
stones or the possible renal toxicity of elevated levels of UA (41). 
Comorbidities affect gout management, and gout affects the management of the other 
diseases. A clear example is aspirin, which is cardioprotective but at the same time 
increases uricemia. At the same time, drug treatment of hypertension is related to an 
increased risk of developing gout (beta-blockers, angiotensin converter enzyme 
inhibitors, and some tubular loop diuretics)(42). However, insulin-lowering drugs and 
dyslipidemia management drugs present benefits for gout patients since they have 
urate-lowering effects (19). 
The other way around, colchicine and NSAIDs are not recommended in patients with 
renal failure and steroids cannot be given to patients with metabolic syndrome, 
hypertension or diabetes mellitus type 2 (41). Also, colchicine and statins (a drug used 
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for the treatment of dyslipidemias) should not be given together in patients with renal 
failure because of a metabolic interaction (they compete for the same metabolic 
enzyme)(10).   
There are some interactions with urate-lowering therapy too. For example, furosemide, 
a drug used in heart failure, decreases the allopurinol hypouricemic effects, by blocking 
the allopurinol reduction of XO expression (a new mechanism just found) (10,36). In the 
case of chronic kidney disease, allopurinol dose should be considered because it can 
cause serious cutaneous skin reactions, but reducing the dose for avoiding skin 
reactions, it will difficult to reach the desired uricemia levels. The normal procedure then 
dictates a switch to febuxostat (36). 
 
4.8. Dietary management of gout 
 
Although there are well documented pharmacological treatments for gout, the role of 
the diet for management is basic to properly control this disease. Diet is a key factor for 
patients to have an improvement in quality of life and to minimize the pharmacological 
treatments and their side effects. Historically, diet control was based on cutting high 
purine foods out of the diet, reducing the amount of exogenous purine intake (12). But 
as is already discussed in this paper, there are many other factors which can affect UA 
and not all the rich purine foods affect uricemia the same way (12–14). Also, is it 
important to look to at the type of purines present in each food (adenine, guanine, 
hypoxanthine, and xanthine), because adenine and particularly hypoxanthine are known 
to be more uricogenic, than guanine and xanthine (43).   
Right now, most nutrition guidelines or recommendations focus on different aspects of 
food and liquid intake. In general, there are common factors which are present in gout 
diets, limiting or avoidance of alcohol; losing weight if the person is obese (as it is said 
before high-fat levels in the body increases the metabolic syndrome and uricemia 
levels); reducing the fructose intake by sweetened drinks (sodas) and juices (17); 
reducing purine intake from red meats and seafood; including dairy products, 
particularly low fat; and maybe introducing vitamin C supplementation (44). 
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There are also recommendations that will impact a flare development. The patient 
should avoid alcohol, drink water (between 8-16 cups)/day and consume less than 170 
mg of meat a day as well as avoiding seafood (43). Then as a protein source, eggs (0 mg/ 
100mg of purine content), low-fat dairy and tofu (20 mg/100mg) should be considered 
(13). On the other hand, there are long term recommendations, which include weight 
loss and daily exercise, increasing protein from plants, fruits, and whole grains, one or 
two servings of low-fat dairy daily, decreasing or eliminating beer, liqueur, and high 
fructose beverages and finally consider drinking coffee and taking vitamin C (43).  
4.8.1. Low-purine diet 
Low purine diet was the first diet introduced in gout management because it decreases 
circulating UA levels 1-2 mg/dL (11). But nowadays, they are not used anymore because 
of increased fat and carbohydrate intake, which can increase comorbidity problems. 
Also, there are some foods which have a high level of purines, for example, some 
vegetables and legumes, but are not related with an increase in uricemia and risk of 
gout. They would be avoided in this type of diet just because of the high concentration 
of purines that they contain (43).  
4.8.2. Plant-based diet 
This type of diet is based on consumption of whole grains, legumes, fruits, and 
vegetables. Considering that vegetables with high purine content do not affect uricemia 
in the same way animal purine does, there is no need to exclude high purine content 
vegetable and legumes (43,44). In beans, vegetables, and soy products, more than 60% 
of the purine type is adenine and guanine while in the animal products more than 50% 
is hypoxanthine (43). Vegetarians always show lower UA in circulation than the non-
vegetarians. Ironically a vegan diet might be expected to have lower UA levels than a 
vegetarian diet, but it shows a higher uricemia than a nonvegetarian diet (13). This is 
related to the fact that in a vegan diet there is no consumption of dairy products, which 
helps to reduce the uricemia, as explained before (45). Plant based diets are not only 
worth it for the management of gout and hyperuricemia but they also works for gout 
comorbidities and are one of the principal components of the dietary approaches to stop 
hypertension (44) . 
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4.8.3. Weight-loss diet 
Obesity is related to high levels of uricemia, this relationship could be due to multiple 
factors such as an increment of the oxygen demand, an increase of endogenous purines 
because of the synthesis of fatty acids and a reduction in renal urate excretion (11). One 
study on coronary artery disease risk development in young adults showed that 
overweight people are 3 to 9 times more likely to develop hyperuricemia(46). Loss of fat 
mass is directly relating to reaching the desired UA levels in the blood, so weight loss 
diets must be considered. The hypouricemic effect of weight loss depends on the 
amount of weight loss and the initial uricemia (47). In common with plant-based diet, it 
also will help to deal with cardiovascular and kidney diseases. 
 
4.9.  Patient interview analysis 
 
(Interview available in the Annex) 
Interview: The patient is a 58 years old Caucasian man, from Spain, 76 kg weight and 
1,60m tall, follows the Mediterranean diet with some excesses sometimes. As well as 
gout, he presents other comorbidities such as over-weight (BMI = 76 kg / 1, 60m2 = 29,6) 
and moderate hypertension. 
The content of the interview, in general matches with the content of this paper. There 
are slight variations in some topics since that every patient is different, and fitting 
everyone into the same characteristics for a disease is almost impossible. The patient 
characteristics (age, ethnicity, comorbidities and weight) also match with the gout 
patient prototype (1).  
The patient looks well informed about gout and he explains quite well the disease in his 
own words. Even if there are some conceptual mistakes, the general idea of the disease 
is clear. However, the concept of the chronic nature of the disease does not appear in 
his definition. As said before in this paper, communicating this concept to the patients 
is basic to assure a good treatment adherence (35). The year of diagnosis and symptoms 
described in the interview are the ones expected considering the information provided 
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by this paper, despite the description of the first attack, which the patient already said 
was unusual. 
The interview description of flares is also the one expected. The treatment helps to 
reduce the time a flare lasts, and also the patient can feel when an attack would start in 
the next few hours. Interestingly there are not consistent periods between flares. It is a 
random process, which means that variations in food intake or metabolic changes, could 
be responsible. The patient only takes medication for the flares, which means that he 
has no problems controlling the UA blood levels, because he does not need therapy with 
urate-lowering drugs.  
The eating habits of this patient follow the Mediterranean diet, which is considered one 
of the best diets in the world (48), and it is probably what helped the patient to avoid 
the urate-lowering drugs. He is aware that there are some foods which are negatively 
related with gout, he relates it to an attack and not the increase of the UA levels, which 
is the main consequence.  
He has taken some foods out of the diet: beer, sweetened drinks, and red meat. The 
patient had introduced these changes 6 months ago and has not experienced any flare, 
so probably there is a positive relation between these two situations. An important 
factor, which the patient talks about and is not discussed in this paper, is to have regular 
eating hours. He says before he started to control eating times, the flares were more 











Different topics related with gout have been discussed in this paper, allowing for an 
overall analysis of the disease. This study has provided a general analysis and overview 
of gout establishing the key points for understanding the disease, its consequences, and 
the different ways to treat it.  
1. Databases have been properly applied during the project. All the different tools and 
research methods have followed the directions given, and only reliable sources have 
been consulted.  The article selection criteria have been developed properly, and 
only the most relevant articles and sources have been selected. Finally, using the 
reference manager Mendeley and following the Vancouver citation rules, the 
references have been properly cited and managed. 
 
2. Gout is a disease that involves a large number of different mechanisms and 
metabolic pathways. Different systems in the body take part; the liver, the kidney, 
the gut and the joints (1). These characteristics mean that even though the disease 
has been documented and studied for years, there are still some parts that require 
more research. This will allow for a better awareness of the signs and symptoms of 
the disease, simplifying the complex diagnoses that are used right now, allowing for 
an improved treatment.  
 
3. Food plays a basic, yet important role in gout management, treatment and 
prevention (12). A proper control of the diet helps to reduce UA levels, as well as 
manage gout comorbidities. On one hand, not all the foods which have a high purine 
content end up increasing the UA blood levels, it depends on the cooking practice 
used and the type of purine presented. On the other hand, if a food contains no 
purines it does not mean it would not affect the UA levels, as seen with soft drinks. 
There are many other foods that help to reduce UA circulating levels by different 
mechanisms, for example, dairy products and coffee. Finally, the anti-inflammatory 
properties of some foods should be considered to reduce flare frequencies, making 




4. Gout drug treatment can be separated into two big families; urate-lowering therapy 
and acute gout treatment (4). Both use different drugs which act in different ways. 
Although the drugs used right now are effective in reducing a flare period or 
decreasing the UA circulating levels, further research needs be carried out into the 
treatment of the disease. This is because gout is a chronic disease, which means 
there is no cure at the moment.  
 
5. Comorbidities are important factors to consider in gout management (36). 
Metabolic syndrome, cardiovascular disease, and kidney disease are related to gout 
and high UA levels. The main problem with these different co-existing diseases is the 
interactions between them and their treatments. This is one of the reasons why 
treatment via the diet is important for gout.  
 
6. Gout is a chronic, metabolic, and inflammatory disease related to different 
comorbidities and different recommendations will help its management. These 
include; keeping the patient well informed about the disease and its consequences, 
properly analyzing any other health problems the patient may present and how they 
would affect gout management ,if pharmacological treatment is necessary choose 
the most appropriate one based on the patient health status, and finally, looking 
into the dietary habits of the patient and make the necessary corrections to achieve 
appropriate UA serum levels. 
In conclusion, all the associated objectives for this project had been achieved. The 
hypothesis of the paper appeared to be partially confirmed. As it is discussed, diet 
appears to be as important as drug treatments for reducing serum UA, presenting strong 
evidence that proper control in food intake could be as effective as urate-lowering 
drugs. Despite the anti-inflammatory properties of some foods that can reduce flare 
frequencies, when a flare attack occurs, it seems that pharmacological treatment is 
needed since food response is not quick enough. This seems to make drug treatment 
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1. What do you know about your pathology? 
 
I know that gout is an inflammatory disease, linked with a high blood levels of 
uric acid. I think that my body eliminates less uric acid than a normal person, this 
increases the uric acid blood levels and then crystals of this substance are formed 
in the joints. Once the crystals are formed an attack of gout appears and it is 
extremely painful.  
 
2. How old were you when you got diagnosed? 
 
I was 44 years old 
 
3. Which were the symptoms you felt? 
 
I am a bizarre case, because if normally the gout starts in a toe or in a knee, I 
noticed in the external part of my left foot. It was an uncomfortable and painful 
feeling, that didn’t even allow me to walk, so I thought I had broken a bone. When 
I arrived to the doctor they didn’t think on gout for the first moment, because 
they thought it was a trauma problem and it wasn’t till the rheumatologist 
suspect of gout, and ordered a blood analysis that they found out. 
 
4. What is normally the period between one flare and the next? 
 
There is no period exactly between flares, for example right now I did not 
experience one for the last 6 months, but when I was diagnosed the first time, I 
got an attack every 2 months, more or less. I will say that is random but 
sometimes if I do an abuse of feasting for 3 days, is more likely an attack will 
appear.  
 
5. How long does a flare last? 
 
Right now, because I take medication, the acute part of a flare, which is when I 
can barely move, only lasts for 24h, and then 3 more days till the symptoms 
totally disappear. However, the first times I was not being treated the acute part 




6. Can you notice if a flare is about to occur 24h before? 
 
Yes. Normally the feeling comes when I’m going to sleep, it feels warm and a little 
bit itchy around a joint area, is not uncomfortable at all, but in general when this 
appears I normally got a flare next morning, but its good because it helps me 
reacting to the attack before it even occurs.   
 
 
7. Which treatment are you on? Do you know the mechanism of action of the 
drugs? 
 
My treatment consists only in two medications for the flare, colchicine and 
naproxen, for the gout treatment. Then I also take a drug for help regulating the 
hypertension called enalapril.  
 
8. Is the treatment effective? 
 
Is not effective on reducing the pain, because every time I have an attack the 
feeling that I got is exactly the same. Although, is really helpful on reducing the 
time a flare lasts, as I said before, the treatment reduces the time an attack will 
last.  
 
9. Are there any foods that if you eat will bring on a flare? 
 
I know there are some foods that helps an attack happen, like red meat or peas, 
but in general I can eat some of that in moderation and nothing happens to me. 
However, as I also commented before, when I do an excess in feasting like 
Christmas celebrations, when I eat a lot of heavy and sugary foods and I also drink 
a lot of alcohol, is more likely for me to have an attack the days after.  
 
10. What was your diet before getting diagnosed? Have you changed something 
since then? 
 
My diet before getting diagnoses is more or less the same I have right now. 
However, is it true that I have delete some foods or drinks, not only because of 
gout, also for the high levels of sugar. I try to moderate my alcohol intake and 
drink more wine than beer, also I have deleted the sweetened drinks like coke or 
sprite 6 months ago. However, if one day I want to eat something I do, I don’t 
deprive myself of nothing. I tried to reduce my red meat intake, because before I 
used to eat at least one piece every day. And the most important think is 
managing properly the food hours. Before I got diagnosed and the 5 years after I 
 
was quite chaotic in my eating hours, I used to skip breakfast and don’t eat 
anything during the morning till lunch, and it was the period when I have 
experienced more attacks. Right now, I try to have at least 5 meals a day, 3 
important ones and 2 small ones between the other 3.  
 
11. Is there any food you cannot take because of the medication? 
 
I know alcohol is not recommended but that’s it.  
 
 
 
 
 
 
 
 
 
 
 
 
